Top

Quality of Life Research

Gepubliceerd in:

01-08-2008

Evidence on the construct validity of the Health Utilities Index Mark 2 and Mark 3 in patients with chronic kidney disease

Auteurs: Sara N. Davison, Gian S. Jhangri, David H. Feeny

Gepubliceerd in: Quality of Life Research | Uitgave 6/2008

Abstract

Objective

This study assessed the construct validity of the Health Utilities Index Mark 2 (HUI2) and Mark 3 (HUI3) in the context of chronic kidney disease (CKD) and compared their ability to discriminate between groups of patients with varying disease severity.

Study design and setting

The HUI2 and HUI3 were correlated with the Medical Outcomes 36-Item Short-Form, Kidney Disease Quality of Life Questionnaire, and the Beck Depression Inventory II in 185 patients with stage 4 and 5 CKD.

Results

About 86% of a priori hypotheses were confirmed for HUI2 and 95% for HUI3, providing support for the construct validity of both measures. Mean (SD) overall utility score for the HUI2 was 0.74 (0.20), significantly higher than that for the HUI3, 0.58 (0.26) (P < 0.001). The cognitive, emotion, and pain attributes of the HUI3 were able to identify a significantly greater proportion of patients with impairment compared to the HUI2.

Conclusion

The results are consistent with construct validity for the HUI2 and HUI3 in patients with stage 4 and 5 CKD. However, the HUI3 appears to have superior psychometric properties compared with the HUI2 in this patient population.

vorige artikel Measuring breast cancer-specific health-related quality of life in South Asia: psychometric properties of the Sinhala version of the EORTC QLQ-BR23

volgende artikel Health state preference scores for children with permanent childhood hearing loss: a comparative analysis of the QWB and HUI3

Alleen toegankelijk voor geautoriseerde gebruikers

DeOreo, P. B. (2001). The use of patient-based instruments to measure, manage, and improve quality of care in dialysis facilities. Advances in Renal Replacement Therapy, 8(2), 125–130.PubMedCrossRef

Ifudu, O., Paul, H. R., Homel, P., & Friedman, E. A. (1998). Predictive value of functional status for mortality in patients on maintenance hemodialysis. American Journal of Nephrology, 18(2), 109–116.PubMedCrossRef

McClellan, W. M., Anson, C. A., Birkeli, K., & Tuttle, E. (1991). Functional status and quality of life: Predictors of early mortality among patients entering treatment for end stage renal disease. Journal of Clinical Epidemiology, 44(1), 83–89.PubMedCrossRef

Hays, R. D. (1998). R36 H.S.I. Rand 36—36 health status inventory. Harcourt Brace & Company.

Hays, R. D., Kallich, J. D., Mapes, D. L., Coons, S. J., Amin, N., Carter, W. B., et al. (1997). Kidney disease quality of life short form (dkqol-sf), version 1.3: A manual for use and scoring. Santa Monica, CA: RAND.

Annual Data Report. (2007). Atlas of end-stage renal disease in the United States. American Journal of Kidney Diseases, 49(Supplement 1), S1–S239.

Trivedi, H. S., Pang, M. M., Campbell, A., & Saab, P. (2002). Slowing the progression of chronic renal failure: Economic benefits and patients’ perspectives. American Journal of Kidney Diseases, 39(4), 721–729.PubMedCrossRef

Lenert, L., & Kaplan, R. M. (2000). Validity and interpretation of preference-based measures of health-related quality of life. Medical Care, 38(9 Suppl), II138–II150.PubMed

Petrou, S., & Hockley, C. (2005). An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Economics, 14(11), 1169–1189.PubMedCrossRef

10.

Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.PubMedCrossRef

11.

Feeny, D., Torrance, G. W., & Furlong, W. (1996). Quality of life and pharmacoeconomics in clinical trials. In B. Spilker (Ed.), Health utilities index (pp. 239–51). Philadelphia, PA: Lippincort-Raven.

12.

Furlong, W. J., Feeny, D. H., Torrance, G. W., & Barr, R. D. (2001). The Health utilities index (HUI) system for assessing health-related quality of life in clinical studies. Annals of Medicine, 33(5), 375–384.PubMedCrossRef

13.

Torrance, G. W., Feeny, D. H., Furlong, W. J., Barr, R. D., Zhang, Y., & Wang, Q. (1996). Multiattribute utility function for a comprehensive health status classification system. Health utilities index mark 2. Medical Care, 34(7), 702–722.PubMedCrossRef

14.

Ware, J. E. Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.PubMedCrossRef

15.

Ware, J. E. (1993). SF-36 Health survey: Manual and interpretation guide. Boston, MA: New England Medical Centre.

16.

Beck, A. T., Steer, R. A., & Brown, G. K. (1996). BDI-II manual (2nd ed.). San Antonio, Texas: Harcourt Brace.

17.

Kimmel, P. L. (2001). Psychosocial factors in dialysis patients. Kidney International, 59(4), 1599–1613.PubMedCrossRef

18.

Newmann, S. P. (2002). A randomised controlled trial of a psychological intervention to promote emotional expression and adaptation in individuals with chronic renal failure (CRF) and end stage renal disease (ESRD). UK: National Research Registry.

19.

Kimmel, P. L. (2000). Psychosocial factors in adult end-stage renal disease patients treated with hemodialysis: Correlates and outcomes. American Journal of Kidney Diseases, 35(4), S132–S140.PubMedCrossRef

20.

Zimmermann, P. R., Camey, S. A., & Mari, J. J. (2006). A cohort study to assess the impact of depression on patients with kidney disease. International Journal of Psychiatry in Medicine, 36(4), 457–468.PubMedCrossRef

21.

Hedayati, S. S., Bosworth, H. B., Kuchibhatla, M., Kimmel, P. L., & Szczech, L. A. (2006). The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney International, 69(9), 1662–1668.PubMedCrossRef

22.

Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373–383.PubMedCrossRef

23.

Van Manen, J. G., Korevaar, J. C., Dekker, F. W., Boeschoten, E. W., Bossuyt, P. M., & Krediet, R. T. (2003). Adjustment for comorbidity in studies on health status in ESRD patients: Which comorbidity index to use? Journal of the American Society of Nephrology, 14(2), 478–485.PubMedCrossRef

24.

Beddhu, S., Bruns, F. J., Saul, M., Seddon, P., & Zeidel, M. L. (2000). A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. The American Journal of Medicine, 108(8), 609–613.PubMedCrossRef

25.

Fayers, P. M., & Machin, D. (2000). Quality of life: Assessment, analysis and interpretation. Willey.

26.

Guyatt, G. H., Berman, L. B., Townsend, M., Pugsley, S. O., & Chambers, L. W. (1987). A measure of quality of life for clinical trials in chronic lung disease. Thorax, 42(10), 773–778.PubMedCrossRef

27.

Birbeck, G. L., Kim, S., Hays, R. D., & Vickrey, B. G. (2000). Quality of life measures in epilepsy: how well can they detect change over time? Neurology, 54(9), 1822–1827.PubMed

28.

Johnson, J. A., & Maddigan, S. L. (2004). Performance of the RAND-12 and SF-12 summary scores in type 2 diabetes. Quality of Life Research, 13(2), 449–456.PubMedCrossRef

29.

Taft, C., Karlsson, J., & Sullivan, M. (2001). Do SF-36 summary component scores accurately summarize subscale scores? Quality of Life Research, 10(5), 395–404.PubMedCrossRef

30.

Canadian Organ Replacement Register. (2002). Dialysis and renal transplantation. Ottawa, Ontario: Canadian Institute for Health Information. Report No.: 2001 Report.

31.

Hopman, W. M., Towheed, T., Anastassiades, T., Tenenhouse, A., Poliquin, S., Berger, C., et al. (2000). Canadian normative data for the SF-36 health survey. CMAJ, 163(3), 265–271.PubMed

32.

Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of life. Annals of Internal Medicine, 118(8), 622–629.PubMed

33.

Gorodetskaya, I., Zenios, S., McCulloch, C. E., Bostrom, A., Hsu, C. Y., Bindman, A. B., et al. (2005). Health-related quality of life and estimates of utility in chronic kidney disease. Kidney International, 68(6), 2801–2808.PubMedCrossRef

34.

Foley, R. N., Parfrey, P. S., Morgan, J., Barre, P. E., Campbell, P., Cartier, P., et al. (2000). Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney International, 58(3), 1325–1335.PubMedCrossRef

35.

Heidenheim, A. P., Muirhead, N., Moist, L., & Lindsay, R. M. (2003). Patient quality of life on quotidian hemodialysis. American Journal of Kidney Diseases, 42(1 Suppl), 36–41.PubMedCrossRef

36.

Davison, S. N., Jhangri, G. S., & Feeny, D. (2008). Comparing the health utilities index mark 3 (HUI3) with the short-form 36 preference-based SF-6D in chronic kidney disease. Value in Health (in press).

Titel: Evidence on the construct validity of the Health Utilities Index Mark 2 and Mark 3 in patients with chronic kidney disease
Auteurs: Sara N. Davison
Gian S. Jhangri
David H. Feeny
Publicatiedatum: 01-08-2008
Uitgeverij: Springer Netherlands
Gepubliceerd in: Quality of Life Research / Uitgave 6/2008
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-008-9354-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Objective

Study design and setting

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2008

Separating gains and losses in health when calculating the minimum important difference for mapped utility measures

Letter to the Editor

Persistence of unmet need for care among people with systemic lupus erythematosus: a longitudinal study

A relevant study was missed in our systematic review on the impact of patient-reported outcomes in clinical practice

Measuring breast cancer-specific health-related quality of life in South Asia: psychometric properties of the Sinhala version of the EORTC QLQ-BR23

Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease